Key Insider Increases Stake Following Recent Public Offering
ZBIO has more than doubled off its 52-week low of $6.11.
Summary
A key insider and affiliated entities purchased over $2 million in Zenas BioPharma common stock, increasing their stake to 4.794% following a recent dilutive public offering.
Key Events · Ownership and Investor Activity · ZBIO
-
Insider Purchases
Leon O. Moulder, Jr. and Tellus BioVentures, LLC, an entity he controls, collectively purchased 111,000 shares of common stock for approximately $2.04 million in open-market transactions between February 2 and March 31, 2026.
-
Increased Beneficial Ownership
Leon O. Moulder, Jr. now beneficially owns 3,029,921 shares, representing 4.794% of the company's common stock, including shares held directly, through options, and through affiliated entities.
-
Post-Offering Confidence
The purchases by Tellus BioVentures occurred between March 30-31, 2026, immediately following the company's concurrent public offerings of common stock and convertible notes, which were completed on March 31, 2026, and had previously led to a significant stock price drop.
Analysis · ZBIO · Life Sciences
Leon O. Moulder, Jr., a significant insider, and entities he controls, have collectively purchased over $2 million worth of common stock. These purchases, particularly those by Tellus BioVentures in late March, occurred immediately after the company completed a substantial dilutive public offering and experienced a significant stock price decline. This buying activity signals strong insider confidence in Zenas BioPharma's long-term prospects, despite recent capital raises and market volatility.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZBIO was trading at $21.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.11 to $44.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.